MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

Core Viewpoint - MediWound Ltd. is set to release its financial results for Q4 and the full year ended December 31, 2024, on March 19, 2025, followed by a conference call to discuss these results and provide corporate updates [1][2]. Company Overview - MediWound Ltd. is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, specializing in the development, production, and commercialization of innovative biologics that enhance care standards and improve patient experiences while reducing healthcare costs [3]. Product Information - The company's first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions [4]. - MediWound is advancing EscharEx, a promising candidate currently in Phase III development for chronic wound debridement, which has shown distinct advantages over existing treatments in Phase II trials, presenting a unique opportunity for significant market growth in a $375+ million market [4].